Tissue-specific Cushing's syndrome, 11-β-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action

European Journal of Endocrinology

Volumn 149, Issue 3, 2003, Pages 163-168

  Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; CORTISONE; GLUCOCORTICOID; HYDROCORTISONE; ISOENZYME; MINERALOCORTICOID RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ADIPOSE TISSUE; ARTICLE; BONE; CUSHING DISEASE; CUSHING SYNDROME; ENZYME INHIBITION; ENZYME REGULATION; ESSENTIAL HYPERTENSION; EYE; GENE MUTATION; GLYCYRRHIZA; HORMONE ACTION; HORMONE METABOLISM; HORMONE RECEPTOR INTERACTION; HORMONE SYNTHESIS; HUMAN; IN VIVO STUDY; INSULIN RESISTANCE; KIDNEY DISEASE; LIVER; OBESITY; OMENTUM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; TISSUE SPECIFICITY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADIPOSE TISSUE; CORTISONE; CUSHING SYNDROME; HUMANS; HYDROCORTISONE; HYDROXYSTEROID DEHYDROGENASES; HYPERTENSION; INSULIN RESISTANCE; ISOENZYMES; MODELS, BIOLOGICAL; OBESITY; RECEPTORS, MINERALOCORTICOID;

EID: 0141739647     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1490163     Document Type: Article

References (30)

1. Lakshmi V & Monder C. Purification and characterization of the corticosteroid 11 beta-dehydrogenase component of the rat liver 11 beta-hydroxysteroid dehydrogenase complex. Endocrinology 1988 123 2390-2398.
2. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE & Stewart PM. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. Journal of Clinical Endocrinology and Metabolism 1998 83 1325-1335.
3. Jamieson PM, Walker BR, Chapman KE, Andrew R, Rossiter S & Seckl JR. 11 Beta-hydroxysteroid dehydrogenase type 1 is a predominant 11 beta-reductase in the intact perfused rat liver. Journal of Endocrinology 2000 165 685-692.
4. Bujalska IJ, Kumar S & Stewart PM. Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 1997 349 1210-1213.
5. Shimojo M, Ricketts ML, Petrelli MD, Moradi P, Johnson GD, Bradwell AR et al. Immunodetection of 11 beta-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization. Endocrinology 1997 138 1305-1311.
6. Condon J, Gosden C, Gardener D, Nickson P, Hewison M, Howie AJ et al. Expression of type 2 11beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. Journal of Clinical Endocrinology and Metabolism 1998 83 4490-4497.
7. Palermo M, Shackleton CH, Mantero F & Stewart PM. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology 1996 45 605-611.
8. Ferrari P, Lovati E & Frey FJ. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. Journal of Hypertension 2000 18 241-248.
9. White PC, Mune T & Agarwal AK. 11 Beta-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocrine Reviews 1997 18 135-156.
10. Nunez BS, Rogerson FM, Mune T, Igarashi Y, Nakagawa Y, Phillipov G et al. Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension 1999 34 638-642.
11. Li A, Li KX, Marui S, Krozowski ZS, Batista MC, Whorwood CB et al. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. Journal of Hypertension 1997 15 1397-1402.
12. Agarwal AK, Giacchetti G, Lavery G, Nikkila H, Palermo M, Ricketts M et al. CA-repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension 2000 36 187-194.
13. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ et al. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. Journal of Clinical Endocrinology and Metabolism 1999 84 3745-3749.
14. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH & Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987 2 821-824.
15. Ulick S, Wang JZ, Blumenfeld JD & Pickering TG. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome [see Comments]. Journal of Clinical Endocrinology and Metabolism 1992 74 963-967.
16. Jamieson A, Wallace AM, Andrew R, Nunez BS, Walker BR, Fraser R et al. Apparent cortisone reductase deficiency: a functional defect in 11beta-hydroxysteroid dehydrogenase type 1. Journal of Clinical Endocrinology and Metabolism 1999 84 3570-3574.
17. Biason-Lauber A, Suter SL, Shackleton CH & Zachmann M. Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism. Hormone Research 2000 53 260-266.
18. Nordenstrom A, Marcus C, Axelson M, Wedell A & Ritzen EM. Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11beta-hydroxysteroid dehydrogenase reductase activity. Journal of Clinical Endocrinology and Metabolism 1999 84 1210-1213.
19. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W et al. Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nature Genetics 2003 34 434-439.
20. Rodin A, Thakkar H, Taylor N & Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. New England Journal of Medicine 1994 330 460-465.
21. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E & Connell JM. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999 33 1364-1368.
22. Bujalska IJ, Kumar S, Hewison M & Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology 1999 140 3188-3196.
23. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001 294 2166-2170.
24. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P et al. 11Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. PNAS 1997 94 14924-14929.
25. Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002 45 1528-1532.
26. Tomlinson JW, Sinha B, Bujalska I, Hewison M & Stewart PM. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. Journal of Clinical Endocrinology and Metabolism 2002 87 5630-5635.
27. Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M & Stewart PM. Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone 2000 27 375-381.
28. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. Journal of Bone and Mineral Research 2001 16 1037-1044.
29. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M & Stewart PM. Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. Journal of Bone and Mineral Research 2002 17 979-986.
30. Rauz S, Walker EA, Shackleton CH, Hewison M, Murray PI & Stewart PM. Expression and putative role of 11 beta-hydroxysteroid dehydrogenase isozymes within the human eye. Investigative Ophthalmology and Visual Science 2001 42 2037-2042.